Home  >  Press Releases  >  Most Recent
Share

Press Releases

May 5, 2022
Reports Revenue of $2.0 Billion, Growing 6%, and Net Income of $595 Million, or $1.26 per Diluted Share, Increasing 6% and 8%, Respectively, on a Reported Basis for First Quarter 2022 Delivers 9% Operational Growth in Revenue and 8% Operational Growth in Adjusted Net Income for First Quarter 2022 Reports Adjusted Net Income of $625 Million, or Adjusted Diluted EPS of $1.32, for First Quarter 2022 Updates Full Year 2022 Revenue Guidance to $8.225 - $8.375 Billion, with Diluted EPS of $4.65 to $4.77 on a Reported Basis, or $4.99 to $5.09 on an Adjusted Basis, Due to the Negative Impact of Foreign Exchange Rates Zoetis Inc. (NYSE: ZTS) today reported its financial results for the first quarter of 2022 and updated its guidance for full year 2022 due to the negative impact of recent changes in foreign exchange rates. The updated guidance reflects the same operational growth rates for revenue and adjusted net income as stated in the company’s previous guidance for 2022. The company reported ...
April 19, 2022
First-of-its-kind, multi-purpose technology now offers artificial intelligence (AI) blood smear and fecal testing, along with digital cytology in a single platform, furthering company commitment to diagnostics that drive animal care PARSIPPANY, N.J. – April 19, 2022 – Zoetis today announced its latest innovation in diagnostics with the addition of artificial intelligence (AI) blood smear testing to its multi-purpose platform, Vetscan ImagystTM. Introduced in September 2020, Vetscan Imagyst is a first-of-its- kind technology with a multitude of applications, including AI fecal analysis, digital cytology image transfer and now AI blood smear – ultimately helping veterinarians broaden in-clinic diagnostic offerings to provide the best possible care for dogs and cats. The Vetscan Imagyst AI-driven blood smear capability efficiently delivers critical information that will assist veterinarians in making diagnoses of, and guiding treatment decisions for, animals who are sick or those with ...
April 12, 2022
$4.9 million pledged to 20 initiatives across Africa, Brazil, China, Ukraine and the U.S. Commitments made to support veterinary scholarships, diversity and inclusion programming and mental wellness in the U.S.; livestock farmers and veterinary livelihoods in Africa, Brazil and China; and relief efforts in Ukraine Today, the Zoetis Foundation announced that it will distribute $4.9 million during its first round of 2022 grants, supporting 20 initiatives based in 19 countries to help enable thriving professions and livelihoods for livestock farmers and veterinary professionals as well as relief efforts in Ukraine. Veterinarians, veterinary technicians and livestock farmers provide invaluable services to our communities, raising and caring for animals to be healthy and productive. Yet veterinarians and farmers face immeasurable challenges globally—from rising student debt and a lack of diversity to mental health challenges, including higher risks of suicide. The Zoetis Foundation has ...
March 31, 2022
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 5, 2022. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2022 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on May 5, 2022. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet ...
March 21, 2022
The poultry industry is celebrating a significant milestone in 2022: it is 30 years since in ovo vaccination was used commercially for the first time  Zaventem, Belgium – March 21, 2022 – In 1992, the Inovoject® device launched by Embrex® was a major advance in poultry health, ending the devastating impact of Marek’s Disease on poultry flocks in the United States. Since then, the groundbreaking technology has continued to develop and expand to cover other common poultry diseases complementing the continuum of care for poultry in preventing diseases thanks to automated vaccination.   “Embrex® BioDevices® are now used to inject more than 20 billion eggs every year in 30 countries around the world. And we are incredibly proud of the positive impact it has had since it was first used commercially,” said Glenn David, Executive Vice President and Group President, International Operations, Aquaculture, BioDevices and Pet Insurance . “It has grown from a completely new technology ...
March 16, 2022
As Zoetis CEO Kristin Peck has stated , our global Zoetis community is shocked and saddened by the evolving situation in Ukraine and condemns the invasion and violence there. Our first concern remains the safety of our colleagues and their families in Ukraine, and we continue to closely monitor the situation and do all that we can to support our colleagues as their needs evolve. Our local teams have been assisting colleagues and refugees with re-location, transportation and other needs on the ground there. In terms of humanitarian efforts, our Zoetis colleagues in neighboring countries have been volunteering at the borders to provide veterinary services and donating Zoetis products. We are donating Zoetis vaccines and medicines to veterinarians helping refugees and their pets at the borders, as well as to livestock producers in Ukraine, which will be critical for the health and welfare of those animals and supporting local food production. In addition, the Zoetis Foundation has made ...
March 11, 2022
Zoetis Inc. (NYSE:ZTS) will participate in the Barclays Global Healthcare Conference on Thursday, March 17, 2022. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of ...
March 9, 2022
Recognized for Purpose-driven Innovation in Donating COVID-19 Vaccine for Animals to Zoos Zoetis has been named to Fast Company’s list of Most Innovative Companies for 2022 , ranking eighth in the corporate social responsibility category. Zoetis is the only stand-alone animal health company to be included on this year’s list which honors businesses that are making the biggest impact on their industries and culture as a whole—ultimately thriving in today’s ever-changing world. These companies are creating the future today with some of the most inspiring accomplishments of the 21st century. In addition to the World's 50 Most Innovative Companies, 528 organizations are recognized across 52 categories. The recognition is based on Zoetis’ discovery, development and donation of more than 11,000 doses of its COVID-19 vaccine, developed uniquely for animals, to more than 70 zoos, as well as more than a dozen conservatories, sanctuaries, academic institutions and government organizations, ...
February 22, 2022
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2022 Animal Health Summit on Thursday, Feb. 24, 2022. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:30 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company’s leading portfolio ...
February 15, 2022
For Fourth Quarter 2021, Zoetis Reports Revenue of $2.0 Billion, Growing 9%, and Net Income of $414 Million, or $0.87 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $474 Million, or Adjusted Diluted EPS of $1.00, for Fourth Quarter 2021 Delivers 9% Operational Growth in Revenue and 5% Operational Growth in Adjusted Net Income for Fourth Quarter 2021 For Full Year 2021, Zoetis Reports Revenue of $7.8 Billion, Growing 16%, and Net Income of $2.0 Billion, or $4.27 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $2.2 Billion, or Adjusted Diluted EPS of $4.70 for Full Year 2021 Delivers 15% Operational Growth in Revenue and 19% Operational Growth in Adjusted Net Income for Full Year 2021 Provides Full Year 2022 Revenue Guidance of $8.325 - $8.475 Billion, with Diluted EPS of $4.75 to $4.87 on a Reported Basis, or $5.09 to $5.19 on an Adjusted Basis Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year ...
February 8, 2022
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.325 per share for the second quarter of 2022. The dividend will be paid on Wednesday, June 1, 2022, to all holders of record of the Company’s common stock as of the close of business on Thursday, April 21, 2022. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $6.7 billion in 2020 with approximately 11,300 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES ...
January 31, 2022
Zoetis introduced an expanded precision animal health portfolio at NCBA, including Performance Ranch™, new cow-calf management software, and BLOCKYARD™, innovative blockchain technology PARSIPPANY, N.J. and AMES, IOWA – Jan. 31, 2022 – Precision animal health technology brings data insights together to help cattle producers make earlier, more informed decisions to help keep animals healthy and productive. The newest tools from Zoetis – Performance Ranch™ and BLOCKYARD™ – provide cattle producers the information they need at their fingertips, accessible from digital devices anywhere.  Performance Ranch helps cow-calf producers easily capture health and performance data, manage costs, and track herd inventory in real time. The new cow-calf management software joins the Performance Beef platform, expanding the software solutions developed by Performance Livestock Analytics for cattle producers. The easy-to-use software provides users insights to make informed decisions across ...
January 13, 2022
Solensia™ is the first and only injectable monoclonal antibody (mAb) treatment for feline OA pain approved in the United States Monthly administration of Solensia controls OA pain by targeting Nerve Growth Factor (NGF), a key driver in OA pain Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Solensia ™ to control the pain of osteoarthritis (OA) in cats, helping improve their mobility, comfort and overall well-being. 1 As a once-monthly injection administered in the veterinary clinic, Solensia keeps OA pain from disrupting the unique bond cats share with their humans. Feline OA, a highly prevalent condition with nearly 40% of all cats showing signs of OA pain 2 , occurs when the protective tissue in the joints (cartilage) is worn down, causing bones to rub together. This makes moving harder and causes severe pain. Without treatment, OA pain can worsen over time and seriously affect a cat’s long-term health and well-being. 3 “Feline OA ...
January 10, 2022
A Convenient Solution to Rapidly and Safely Stop the Cycle of Pruritus in Allergic Dogs and Clinical Signs of Atopic Dermatitis in Dogs ZAVENTEM, BELGIUM, January 10, 2022 – Zoetis announced that the European Commission (EC) has granted the marketing authorization for Apoquel ® chewable tablets (oclacitinib) for dogs for the treatment of clinical manifestations of pruritus associated with allergic dermatitis in dogs and the treatment of clinical manifestations of atopic dermatitis in dogs at least 12 months of age. Pruritus, or itching, is the most common sign of allergies in dogs. The Veterinary Medicines Directorate (VMD) marketing authorization for Great Britain (GB) was received on November 24 th , 2021. “The approval of Apoquel chewable tablets in the European Union provides a convenient new treatment choice for dogs that suffer from allergic skin conditions. This treatment affords an opportunity for the damaged skin to heal, while allowing the veterinarian ample time to identify ...
January 6, 2022
Commits to carbon neutrality in company operations by 2030 Accelerates commitment to 100% renewable energy Zoetis Inc. (NYSE:ZTS), the world’s leading animal health company, has refreshed its Driven to Care sustainability aspirations for mitigating the company’s climate impact and environmental effects on the planet. Focusing first on its own operations, Zoetis is striving to achieve carbon neutrality by 2030. This includes accelerating the company’s commitment to Renewable Energy 100 (RE100) to use 100% renewable energy in its operations. The company’s updated commitments are underscored by investments in technology and a strong governance structure. “Our vision is to be the most sustainable animal health company in the world, and we are proud to be the first stand-alone animal health company to commit to carbon neutrality by 2030,” said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, Communications and Sustainability at Zoetis. “Launching our expanded climate ...
January 4, 2022
Simparica Trio proven to block the pathogen that causes Lyme disease by killing deer ticks PARSIPPANY, N.J. –January 4, 2022– Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved a new label indication for Simparica Trio ® (sarolaner, moxidectin, and pyrantel chewable tablets) for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks (black-legged or deer ticks).  Simparica Trio is approved for dogs eight weeks of age and older weighing 2.8 pounds and greater. Simparica Trio is the first and only combination product demonstrated to prevent infections that may cause Lyme disease by killing deer or black-legged ticks. “Tick-borne diseases are a serious threat to pets and Lyme disease, caused by Borrelia burgdorferi , is transmitted by deer ticks. It is critical to have easily accessible and effective options for preventing infections available to protect dogs from ticks so ...